Señales en vivo de NVCR | Maximiza tus Ganancias con Getagraph.com

VENDER 108672 min ago

@ $15.54

Emitido: 14 feb 2024 @ 12:55

Retorno: -17.62%

Señal anterior: feb 14 - 12:01

Señal anterior: Comprar

Retorno: 1.34 %

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 16:00):

Stats
Volumen de hoy	957 402
Volumen promedio	1.29M
Capitalización de mercado	1.38B
EPS	$0 ( 2024-02-22 )
Próxima fecha de ganancias	( $-0.420 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.56
ATR14	$0.0100 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Groenhuysen Wilhelmus Cm	Sell	2 107	Ordinary Shares
2024-03-04	Groenhuysen Wilhelmus Cm	Sell	1 217	Ordinary Shares
2024-03-01	Leonard Frank X	Sell	1 679	Ordinary Shares
2024-03-04	Leonard Frank X	Sell	840	Ordinary Shares
2024-02-27	Cordova Ashley	Buy	102 249	Ordinary Shares

INSIDER POWER
77.64
Last 92 transactions
Buy: 1 705 026 \| Sell: 238 995

Volumen Correlación

Largo: -0.29 (neutral)

Corto: -0.74 (moderate negative)

Signal:(35.119) Neutral

Novocure Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novocure Ltd Correlación - Moneda/Commodity

0.48
( neutral )

0.36
( neutral )

0.00
( neutral )

0.46
( neutral )

-0.54
( weak negative )

Novocure Ltd Finanzas

Annual	2023
Ingresos:	$509.34M
Beneficio Bruto:	$381.06M (74.81 %)
EPS:	$-1.950

FY	2023
Ingresos:	$509.34M
Beneficio Bruto:	$381.06M (74.81 %)
EPS:	$-1.950

FY	2022
Ingresos:	$537.84M
Beneficio Bruto:	$422.97M (78.64 %)
EPS:	$-0.880

FY	2021
Ingresos:	$535.03M
Beneficio Bruto:	$420.15M (78.53 %)
EPS:	$-0.563

Financial Reports:

No articles found.

Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Actualizaciones en tiempo real para Novocure Ltd [NVCR]

Upcoming Earnings Alert